ASX - By Stock
|
SPL |
Re:
New CEO’s focus
|
|
stoway
|
85 |
19K |
0 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
85
|
19K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
New CEO’s focus
|
|
stoway
|
85 |
19K |
1 |
08/01/24 |
08/01/24 |
ASX - By Stock
|
85
|
19K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Radiopharmaceuticals
|
|
stoway
|
3 |
1.3K |
4 |
06/01/24 |
06/01/24 |
ASX - By Stock
|
3
|
1.3K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
History
|
|
stoway
|
83 |
15K |
0 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
83
|
15K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
NECTA Dangerous Ideas in Drug Apl
|
|
stoway
|
5 |
1.3K |
0 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
5
|
1.3K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs new DEP partnership with Chase Sun
|
|
stoway
|
95 |
31K |
3 |
28/12/23 |
28/12/23 |
ASX - By Stock
|
95
|
31K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
AstraZeneca: Acquisitions And Some Thoughts About Biotech Investing
|
|
stoway
|
18 |
4.5K |
0 |
27/12/23 |
27/12/23 |
ASX - By Stock
|
18
|
4.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
stoway
|
131 |
27K |
1 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
131
|
27K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
stoway
|
131 |
27K |
2 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
131
|
27K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
DEATH OR CAPITULATION OF STARPHARMA
|
|
stoway
|
11 |
2.7K |
0 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
11
|
2.7K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Positive DEP docetaxel Phase 2 results
|
|
stoway
|
131 |
27K |
4 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
131
|
27K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Heparin nasal spray trial in Melbourne
|
|
stoway
|
32 |
6.1K |
6 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
32
|
6.1K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Heparin nasal spray trial in Melbourne
|
|
stoway
|
32 |
6.1K |
2 |
17/07/23 |
17/07/23 |
ASX - By Stock
|
32
|
6.1K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma is pursuing registration of Viraleze in China
|
|
stoway
|
56 |
12K |
4 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
56
|
12K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma is pursuing registration of Viraleze in China
|
|
stoway
|
56 |
12K |
2 |
13/07/23 |
13/07/23 |
ASX - By Stock
|
56
|
12K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Where is Docetaxel heading with lung cancer?
|
|
stoway
|
12 |
3.3K |
0 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
12
|
3.3K
|
0
|
|
ASX - By Stock
|
SPL Superannuation |
Re:
New Zealand apparently prescribe Viraleze
|
|
stoway
|
22 |
15K |
0 |
02/07/23 |
02/07/23 |
ASX - By Stock
|
22
|
15K
|
0
|
|
ASX - By Stock
|
SPL Superannuation |
Re:
New Zealand apparently prescribe Viraleze
|
|
stoway
|
22 |
15K |
1 |
01/07/23 |
01/07/23 |
ASX - By Stock
|
22
|
15K
|
1
|
|
ASX - By Stock
|
SPL Superannuation |
Re:
New Zealand apparently prescribe Viraleze
|
|
stoway
|
22 |
15K |
1 |
01/07/23 |
01/07/23 |
ASX - By Stock
|
22
|
15K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
An alternative SPL winning strategy
|
|
stoway
|
5 |
2.2K |
1 |
29/06/23 |
29/06/23 |
ASX - By Stock
|
5
|
2.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Clinical Trial Update
|
|
stoway
|
69 |
20K |
0 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
69
|
20K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Clinical Trial Update
|
|
stoway
|
69 |
20K |
6 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
69
|
20K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
stoway
|
61 |
16K |
1 |
26/06/23 |
26/06/23 |
ASX - By Stock
|
61
|
16K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
stoway
|
61 |
16K |
2 |
23/06/23 |
23/06/23 |
ASX - By Stock
|
61
|
16K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
stoway
|
61 |
16K |
3 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
61
|
16K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
stoway
|
61 |
16K |
0 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
61
|
16K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
stoway
|
61 |
16K |
0 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
61
|
16K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Smear Campains Undermine Share Value
|
|
stoway
|
61 |
16K |
0 |
18/06/23 |
18/06/23 |
ASX - By Stock
|
61
|
16K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma CEO to retire in 2024
|
|
stoway
|
69 |
26K |
4 |
12/06/23 |
12/06/23 |
ASX - By Stock
|
69
|
26K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma signs license for a VivaGel condom in China-SPL.AX
|
|
stoway
|
15 |
5.1K |
1 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
15
|
5.1K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Bit of history for the impatient and disrespectful ones.
|
|
stoway
|
9 |
2.2K |
2 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
9
|
2.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
stoway
|
38 |
10K |
3 |
29/04/23 |
29/04/23 |
ASX - By Stock
|
38
|
10K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: SPL creates slow release soluble DEP remdesivir nanoparticle
|
|
stoway
|
206 |
64K |
0 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
206
|
64K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ann: HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model
|
|
stoway
|
46 |
12K |
2 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
46
|
12K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Small cell lung cancer, we need new treatments.
|
|
stoway
|
9 |
2.2K |
5 |
23/04/23 |
23/04/23 |
ASX - By Stock
|
9
|
2.2K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Small cell lung cancer, we need new treatments.
|
|
stoway
|
9 |
2.2K |
5 |
23/04/23 |
23/04/23 |
ASX - By Stock
|
9
|
2.2K
|
5
|
|
ASX - By Stock
|
SPL |
Re:
Small cell lung cancer, we need new treatments.
|
|
stoway
|
9 |
2.2K |
3 |
22/04/23 |
22/04/23 |
ASX - By Stock
|
9
|
2.2K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
6150 / 12 - AZD0466/AACR
|
|
stoway
|
6 |
2.1K |
6 |
10/04/23 |
10/04/23 |
ASX - By Stock
|
6
|
2.1K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma presents at ASX Small and Mid-Cap Conference
|
|
stoway
|
49 |
12K |
3 |
24/03/23 |
24/03/23 |
ASX - By Stock
|
49
|
12K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Starpharma presents at ASX Small and Mid-Cap Conference
|
|
stoway
|
49 |
12K |
3 |
24/03/23 |
24/03/23 |
ASX - By Stock
|
49
|
12K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
New composition of matter patent for DEP® cabazitaxel
|
|
stoway
|
5 |
1.8K |
5 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
5
|
1.8K
|
5
|
|
ASX - By Stock
|
SPL Biotech |
Re:
Closing my HC account
|
|
stoway
|
31 |
9.7K |
2 |
21/02/23 |
21/02/23 |
ASX - By Stock
|
31
|
9.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Double standards
|
|
stoway
|
11 |
2.4K |
2 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
11
|
2.4K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Pascal Soriot and Starpharma
|
|
stoway
|
16 |
4.2K |
0 |
08/02/23 |
08/02/23 |
ASX - By Stock
|
16
|
4.2K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Pascal Soriot and Starpharma
|
|
stoway
|
16 |
4.2K |
1 |
08/02/23 |
08/02/23 |
ASX - By Stock
|
16
|
4.2K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Dr Russell Basser appointed as non-executive director
|
|
stoway
|
18 |
4.7K |
2 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
18
|
4.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Dr Russell Basser appointed as non-executive director
|
|
stoway
|
18 |
4.7K |
2 |
31/01/23 |
31/01/23 |
ASX - By Stock
|
18
|
4.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Viraleze.com
|
|
stoway
|
6 |
1.7K |
1 |
27/01/23 |
27/01/23 |
ASX - By Stock
|
6
|
1.7K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Everyone locked and loaded???
|
|
stoway
|
28 |
9.0K |
1 |
26/01/23 |
26/01/23 |
ASX - By Stock
|
28
|
9.0K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Is it broken
|
|
stoway
|
16 |
4.9K |
1 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
16
|
4.9K
|
1
|
|